

AN INHALED FORMULATION OF FDA-APPROVED DRUGS FOR TREATMENT OF ARDS (Hadasit)

code: 8-2020-504

Rifaat Safadi, Hadassah Ein Kerem, Department of Medicine, Gastroenterology

Prof. Rifaat Safadi and his team are developing an inhaled formulation that combines two FDA-approved drugs, which recruit and activate certain types of immune cells in patients with Acute Respiratory Distress Syndrome (ARDS).

The inhaled formulation will enable a safer use of the drugs locally in the lung.

The drugs are expected to exert a synergistic action.

Prof. Safadi's team is planning to clinically test the drugs separately and in the combined inhaled form in patients, for the benefit of COVID-19 patients.

Contact for more information:

Tal Almog , 054-3187538

Hadasit Medical Research Services & Development Ltd

Mother & Child Pavilion, Hadassah Ein Kerem, Jerusalem , 91120 Israel

Phone: +972-2-6778757, Fax: +972-2-6437712, E-mail: skimhi@hadassah.org.il